PROPANC BIOPHARMA, INC. (PPCB) Net income 2017–2026
PROPANC BIOPHARMA, INC. (PPCB) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.
-$18.9MFY2026 · since FY2017: -$7.9M → -$18.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -$18.9M | +68.0% |
| FY2025 | -$58.9M | -3136.6% |
| FY2024 | -$1.8M | +31.6% |
| FY2023 | -$2.7M | -0.1% |
| FY2022 | -$2.7M | -31.2% |
| FY2021 | -$2.0M | +57.3% |
| FY2020 | -$4.7M | +17.7% |
| FY2019 | -$5.8M | +18.2% |
| FY2018 | -$7.0M | +10.5% |
| FY2017 | -$7.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More PPCB financial trends
PPCB RevenuePPCB Net marginPPCB Gross profitPPCB Gross marginPPCB Operating incomePPCB Operating marginPPCB Operating cash flowPPCB Free cash flowPPCB Capital expendituresPPCB Return on equityPPCB Stock buybacksPPCB Dividends paidPPCB Total assetsPPCB Total liabilitiesPPCB Shareholders’ equityPPCB overview →